AGIO — Agios Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.94bn
- $1.05bn
- $36.50m
- 48
- 66
- 78
- 69
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.32 | ||
| Price to Tang. Book | 1.32 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 52.34 | ||
| EV to EBITDA | 1.6 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 43.17% | ||
| Return on Equity | 60.26% | ||
| Operating Margin | 1751.97% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 14.24 | 26.82 | 36.5 | 43.76 | 139.69 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Directors
- David Schenkein CHM (63)
- Jacqualyn Fouse CEO (59)
- Jonathan Biller CFO (57)
- T. J. Washburn CAO (40)
- Bruce Car CSO (59)
- Sarah Gheuens OTH
- Richa Poddar OTH
- John Maraganore LED (58)
- Paul Clancy IND (59)
- Ian Clark IND (60)
- Kaye Foster IND
- Maykin Ho IND (68)
- David Scadden IND (68)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 7th, 2007
- Public Since
- July 24th, 2013
- No. of Shareholders
- 9
- No. of Employees
- 486
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 57,915,199
- Address
- 88 Sidney Street, CAMBRIDGE, 02139
- Web
- https://www.agios.com/
- Phone
- +1 6176498600
- Contact
- Christopher Taylor
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for AGIO
Q3 2025 Agios Pharmaceuticals Inc Earnings Release
Similar to AGIO
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Agios Pharmaceuticals share price?
As of Today at 19:07 UTC, shares in Agios Pharmaceuticals are trading at $33.47. This share price information is delayed by 15 minutes.
How has the Agios Pharmaceuticals share price performed this year?
Shares in Agios Pharmaceuticals last closed at $33.47 and the price had moved by -23.25% over the past 365 days. In terms of relative price strength the Agios Pharmaceuticals share price has underperformed the S&P500 Index by -32.11% over the past year.
What are the analyst and broker recommendations for Agios Pharmaceuticals?
The overall consensus recommendation for Agios Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Agios Pharmaceuticals dividend yield?
Agios Pharmaceuticals does not currently pay a dividend.
Does Agios Pharmaceuticals pay a dividend?
Agios Pharmaceuticals does not currently pay a dividend.
When does Agios Pharmaceuticals next pay dividends?
Agios Pharmaceuticals does not currently pay a dividend.
How do I buy Agios Pharmaceuticals shares?
To buy shares in Agios Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Agios Pharmaceuticals?
As of the previous close price of $33.47, shares in Agios Pharmaceuticals had a market capitalisation of $1.94bn.
Where are Agios Pharmaceuticals shares listed?
Here are the trading details for Agios Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: AGIO
What kind of share is Agios Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Agios Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Agios Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Agios Pharmaceuticals is $54.00. That is 61.34% above the last closing price of $33.47.
Analysts covering Agios Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$7.24 for the next financial year.
Find out moreWhat is the trend in the Agios Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agios Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -4.11%.
As of the last closing price of $33.47, shares in Agios Pharmaceuticals were trading -11.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Agios Pharmaceuticals PE Ratio?
The Agios Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $33.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Agios Pharmaceuticals?
Agios Pharmaceuticals' management team is headed by:
- David Schenkein - CHM
- Jacqualyn Fouse - CEO
- Jonathan Biller - CFO
- T. J. Washburn - CAO
- Bruce Car - CSO
- Sarah Gheuens - OTH
- Richa Poddar - OTH
- John Maraganore - LED
- Paul Clancy - IND
- Ian Clark - IND
- Kaye Foster - IND
- Maykin Ho - IND
- David Scadden - IND